Tags

Type your tag names separated by a space and hit enter

[Local drugs in treating and decreasing the incidence of adverse reactions after sclerotherapy of telangiectasia].
Angiol Sosud Khir. 2019; 25(4):102-107.AS

Abstract

AIM

The purpose of the study was to assess efficacy and safety of heparin sodium gel 1000 IU/g and Detragel® in decreasing the incidence and treatment of the most common local adverse reactions in patients after endured sclerotherapy of reticular veins and telangiectasias.

PATIENTS AND METHODS

Our open prospective observational study included a total of sixty 18-to-35-year-old female patients who after undergoing standardized sclerotherapy of reticular veins and telangiectasias on symmetrical portions of lower limbs were given a tube of heparin sodium gel 1000 IU/g or Detragel® to be applied onto the skin of one (left) lower limb in the projection of the sclerotherapy-exposed vessels 2-3 times daily for 10 days followed by putting on a compression class 2 (RAL standard) stocking. The women were allowed to use only the paired stocking on the contralateral extremity. Efficacy and safety of heparin sodium gel 1000 IU/g and Detragel® were evaluated based on the incidence of typical adverse reactions (ecchymoses, phlebitides, hyperpigmentation and neovasculogenesis), as well as on the patient's subjective perceptions.

RESULTS

The use of heparin sodium gel 1000 IU/g and Detragel® in addition to compression after sclerotherapy of reticular veins and telangiectasias significantly and comparably decreased the incidence and accelerated the resolution of ecchymoses and phlebitides associated with phlebosclerosing treatment. The Detragel® group patients were found to develop hyperpigmentation or neovasculogenesis significantly less often as compared with the heparin sodium gel 1000 IU/g group women. What is more, using Detragel® was not accompanied by hyperkeratosis, pruritus or formation of a sticky film, the events, however, observed while applying heparin sodium gel 1000 IU/g.

CONCLUSION

The use of Detragel® or heparin sodium gel 1000 IU/g for 10 days additionally to compression significantly decreased the incidence of typical undesirable reactions associated with sclerotherapy of reticular veins and telangiectasias. The Detragel® group women turned out to have lower incidence of hyperpigmentation and neovasculogenesis. Besides, Detragel® demonstrated better organoleptic properties.

Authors+Show Affiliations

Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia; First Phlebological Centre, Moscow, Russia.Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia.Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia.First Phlebological Centre, Moscow, Russia.

Pub Type(s)

Journal Article
Observational Study

Language

rus

PubMed ID

31855206

Citation

Bogachev, V Iu, et al. "[Local Drugs in Treating and Decreasing the Incidence of Adverse Reactions After Sclerotherapy of Telangiectasia]." Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, vol. 25, no. 4, 2019, pp. 102-107.
Bogachev VI, Boldin BV, Turkin PI, et al. [Local drugs in treating and decreasing the incidence of adverse reactions after sclerotherapy of telangiectasia]. Angiol Sosud Khir. 2019;25(4):102-107.
Bogachev, V. I., Boldin, B. V., Turkin, P. I., & Lobanov, V. N. (2019). [Local drugs in treating and decreasing the incidence of adverse reactions after sclerotherapy of telangiectasia]. Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 25(4), 102-107. https://doi.org/10.33529/ANGIO2019405
Bogachev VI, et al. [Local Drugs in Treating and Decreasing the Incidence of Adverse Reactions After Sclerotherapy of Telangiectasia]. Angiol Sosud Khir. 2019;25(4):102-107. PubMed PMID: 31855206.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Local drugs in treating and decreasing the incidence of adverse reactions after sclerotherapy of telangiectasia]. AU - Bogachev,V Iu, AU - Boldin,B V, AU - Turkin,P Iu, AU - Lobanov,V N, PY - 2019/12/20/entrez PY - 2019/12/20/pubmed PY - 2020/1/17/medline KW - Detragel® KW - heparin sodium gel 1000 IU/g KW - sclerotherapy SP - 102 EP - 107 JF - Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery JO - Angiol Sosud Khir VL - 25 IS - 4 N2 - AIM: The purpose of the study was to assess efficacy and safety of heparin sodium gel 1000 IU/g and Detragel® in decreasing the incidence and treatment of the most common local adverse reactions in patients after endured sclerotherapy of reticular veins and telangiectasias. PATIENTS AND METHODS: Our open prospective observational study included a total of sixty 18-to-35-year-old female patients who after undergoing standardized sclerotherapy of reticular veins and telangiectasias on symmetrical portions of lower limbs were given a tube of heparin sodium gel 1000 IU/g or Detragel® to be applied onto the skin of one (left) lower limb in the projection of the sclerotherapy-exposed vessels 2-3 times daily for 10 days followed by putting on a compression class 2 (RAL standard) stocking. The women were allowed to use only the paired stocking on the contralateral extremity. Efficacy and safety of heparin sodium gel 1000 IU/g and Detragel® were evaluated based on the incidence of typical adverse reactions (ecchymoses, phlebitides, hyperpigmentation and neovasculogenesis), as well as on the patient's subjective perceptions. RESULTS: The use of heparin sodium gel 1000 IU/g and Detragel® in addition to compression after sclerotherapy of reticular veins and telangiectasias significantly and comparably decreased the incidence and accelerated the resolution of ecchymoses and phlebitides associated with phlebosclerosing treatment. The Detragel® group patients were found to develop hyperpigmentation or neovasculogenesis significantly less often as compared with the heparin sodium gel 1000 IU/g group women. What is more, using Detragel® was not accompanied by hyperkeratosis, pruritus or formation of a sticky film, the events, however, observed while applying heparin sodium gel 1000 IU/g. CONCLUSION: The use of Detragel® or heparin sodium gel 1000 IU/g for 10 days additionally to compression significantly decreased the incidence of typical undesirable reactions associated with sclerotherapy of reticular veins and telangiectasias. The Detragel® group women turned out to have lower incidence of hyperpigmentation and neovasculogenesis. Besides, Detragel® demonstrated better organoleptic properties. SN - 1027-6661 UR - https://www.unboundmedicine.com/medline/citation/31855206/[Local_drugs_in_treating_and_decreasing_the_incidence_of_adverse_reactions_after_sclerotherapy_of_telangiectasia]_ L2 - https://medlineplus.gov/varicoseveins.html DB - PRIME DP - Unbound Medicine ER -